S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%
A daily business newspaper · Founded in 2026

Money Talk

Finance and markets: business, quotes, gold, energy and releases.

Sellas Cancer Vaccine Cuts Death Risk 41% in Phase 3 Trial

Sellas Life Sciences Group said its cancer vaccine galinpepimut-S reduced the risk of death by 41% in a Phase 3 trial involving patients with acute myeloid leukemia. Median overall survival was 24 months with the vaccine, compared with 14.7 months for the best available existing treatment.

Sellas Cancer Vaccine Cuts Death Risk 41% in Phase 3 Trial

The company said Tuesday that the trial met its primary endpoint of overall survival, showing a statistically significant and clinically meaningful improvement. The study tested galinpepimut-S, also known as GPS, as maintenance therapy in patients who had reached a second or later complete remission—or complete remission with insufficient platelet recovery—after second- or later-line salvage therapy and could not undergo allogeneic stem cell transplantation.

GPS was generally well tolerated, Sellas said, with a safety profile consistent with earlier trials. Treatment-related adverse events were predominantly mild to moderate.

Sellas plans to meet with the Food and Drug Administration to discuss the results and the possibility of seeking an accelerated application for the drug. The company also said it would advance preparations for a Biologics License Application submission in the first half of 2027.

“Given the significant unmet need in this patient population, we look forward to engaging with the FDA to discuss the results and the regulatory path forward, with the goal of making this therapy available to patients as rapidly as possible,” Chief Executive Angelos Stergiou said.

Share article
TelegramXFacebook

When reusing this material a link to Money Talk is required.

Comments (0)

Leave a comment

No comments yet. Be the first!